A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Trastuzumab deruxtecan
Related studies linked through entity extraction aliases.
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE3
A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients
- Status
- RECRUITING
- Phase
- PHASE2
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Status
- RECRUITING
- Phase
- PHASE3
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Trial of Trastuzumab Deruxtecan in Previously Treated HER2
- Status
- RECRUITING
- Phase
- PHASE2
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Real-world Study of Trastuzumab Deruxtecan in Patients With Unresectable or Metastatic HER2-low Breast Cancer
- Status
- RECRUITING
- Phase
- N/A
Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
- Status
- RECRUITING
- Phase
- N/A
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
- Status
- RECRUITING
- Phase
- PHASE2
EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
- Status
- RECRUITING
- Phase
- PHASE3
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients
- Status
- RECRUITING
- Phase
- PHASE4
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada
- Status
- COMPLETED
- Phase
- N/A